Cancer52 is a charity and an alliance of patient groups and charities that represent those with rare and less common cancers and our charity, [insert member charity name here], is one of them. You can find out more at www.cancer52.org.uk. Cancer52 is running a survey of patients with rare and less common cancers to find out more about their experiences during the coronavirus pandemic. The survey is available here and is open until Monday 29th June 2020.
Once the survey has finished, Cancer52 will share a full summary of results with its charity members. Cancer52 will also use the results of this survey to understand how the Covid-19 crisis has affected people with rare and less common cancers particularly on topics like treatment and support; any issues around shielding, and anxieties, concerns and hopes for the future. It will use this information in discussions with the Government, the NHS and industry to continue to push for the best possible care and treatment for people with rare and less common cancers.
Answers are anonymous and Cancer52 will not ask you for your name or contact details, although you can, if you wish, opt to keep in touch with Cancer52 and its work at the end of the survey.
The development of this survey has been supported by a grant from GlaxoSmithKline. GlaxoSmithKline have had no editorial input into the content.
Sharing the data with relevant member charities
If Cancer52 receives responses from 20 people or more with the same type of cancer, Cancer52 will share the data collected in this survey on that type of cancer only with the relevant Cancer52 member charity so that they can understand how the pandemic is affecting the specific groups of people they help. The data shared will be non-identifiable.